Skip to main content
AAN.com

Abstract

Objective

To document the decline of upper and lower limb functions, mobility, and independence in daily living activities in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) over a 2-year period.

Methods

An exploratory longitudinal design was used. Nineteen participants were assessed on 2 occasions 2 years apart. Assessments included the Standardized Finger Nose Test, Nine-Hole Peg Test, Lower Extremity Motor Coordination Test, Berg Balance Scale, 10-m walk test (10mWT), 6-minute walk test (6MWT), Scale for the Assessment and Rating of Ataxia (SARA), and Barthel Index.

Results

A significant decline was observed between baseline and follow-up for lower limb coordination, balance, walking abilities (10mWT and 6MWT), and overall disease severity (SARA). All differences were beyond measurement error documented in ARSACS. Results showed no significant decline for upper limb coordination and fine dexterity performance.

Conclusion

Although ARSACS is a slow, progressive disease, results showed that mobility, balance, and lower limb performance significantly decreased over the 2-year period and that selected outcome measures were able to capture this decline beyond measurement errors.

Get full access to this article

View all available purchase options and get full access to this article.

Publication history

Received by Neurology March 27, 2018. Accepted in final form July 4, 2018.

References

1.
Engert JC, Berube P, Mercier J, et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000;24:120–125.
2.
Bouchard JP, Barbeau A, Bouchard R, Bouchard RW. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Can J Neurol Sci 1978;5:61–69.
3.
Gagnon C, Desrosiers J, Mathieu J. Autosomal recessive spastic ataxia of Charlevoix-Saguenay: upper extremity aptitudes, functional independence and social participation. Int J Rehabil Res 2004;27:253–256.
4.
Gagnon C, Mathieu J, Desrosiers J. Standardized finger-nose test validity for coordination assessment in an ataxic disorder. Can J Neurol Sci 2004;31:484–489.
5.
Gagnon C, Lavoie C, Lessard I, et al. The Virtual Peg Insertion Test as an assessment of upper limb coordination in ARSACS patients: a pilot study. J Neurol Sci 2014;347:341–344.
6.
Duquette A, Brais B, Bouchard JP, Mathieu J. Clinical presentation and early evolution of spastic ataxia of Charlevoix-Saguenay. Mov Disord 2013;28:2011–2014.
7.
Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the Assessment and Rating of Ataxia: development of a new clinical scale. Neurology 2006;66:1717–1720.
8.
Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the Nine Hole Peg Test of finger dexterity. Occup Ther J Res 1985;5:24–38.
9.
Gagnon C, Lessard I, Brais B, et al. Validity and reliability of outcome measures assessing dexterity, coordination, and upper limbs strength in autosomal recessive spastic ataxia of Charlevoix-Saguenay. Arch Phys Med Rehabil Epub 2018 Feb 17.
10.
Desrosiers J, Rochette A, Corriveau H. Validation of a new lower-extremity motor coordination test. Arch Phys Med Rehabil 2005;86:993–998.
11.
Lessard I, Lavoie C, Côté I, Mathieu J, Brais B, Gagnon C. Validity and reliability of the LEMOCOT in the adult ARSACS population: a measure of lower limb coordination. J Neurol Sci 2017;377:193–196.
12.
Berg K, Wood-Dauphinee S, Williams JI, Gayton D. Measuring balance in elderly: preliminary development of an instrument. Physiother Can 1989;41:304–311.
13.
Lessard I, Brais B, Côté I, et al. Assessing mobility in autosomal recessive spastic ataxia of Charlevoix-Saguenay population: validity and reliability of four outcome measures. J Neurol Sci 2018;390:4–9.
14.
Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12minute walking tests in respiratory disease. Br Med J 1982;284:1607–1608.
15.
Weyer A, Abele M, Schmitz-Hubsch T, et al. Reliability and validity of the Scale for the Assessment and Rating of Ataxia: a study in 64 ataxia patients. Mov Disord 2007;22:1633–1637.
16.
Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–65.
17.
Winser S, Smith CM, Hale LA, et al. Psychometric properties of a core set of measures of balance for people with cerebellar ataxia secondary to multiple sclerosis. Arch Phys Med Rehabil 2017;98:270–276.
18.
Desrosiers J, Hebert R, Bravo G, Dutil E. Upper-extremity motor co-ordination of healthy elderly people. Age Ageing 1995;24:108–112.
19.
McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J. Reference values for developing responsive functional outcome measures across the lifespan. Neurology 2017;88:1512–1519.

Information & Authors

Information

Published In

Neurology®
Volume 91Number 14October 2, 2018
Pages: e1307-e1311
PubMed: 30158165

Publication History

Received: March 27, 2018
Accepted: July 4, 2018
Published online: August 29, 2018
Published in print: October 2, 2018

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

Funded by the Canadian Institutes of Health Research in partnership with Fondation de l'Ataxie Charlevoix-Saguenay (Emerging Team Grant TR2-119189). C.G. holds career-grant funding from Fonds de recherche du Québec–santé (grants 22193 and 31011).

Authors

Affiliations & Disclosures

Cynthia Gagnon, OT, PhD
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker honoraria from Biogen Idec
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Bioblast Pharma
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) Ataxia Charlevoix-Saguenay Foundation 2) Fondation de ma vie 3) Fonds de dotation sant? Jonqui?re
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Isabelle Lessard, PT, MSc
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Caroline Lavoie, PT, MSc
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Isabelle Côté, MSc
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Raphaël St-Gelais, PT
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
Universit? de Sherbrooke
Research Support, Foundations and Societies:
1.
Programme de d?veloppement de la mission universitaire - Fondation de ma vie
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jean Mathieu, MD, MSc
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Bernard Brais, MD, PhD
From the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.G., I.L., R.S.-G), Centre de recherche Charles-Le Moyne-Saguenay–Lac-Saint-Jean, Faculté de médecine et des sciences de la santé, Université de Sherbrooke; Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (C.L., I.C., J.M.), Centre intégré universitaire de santé et de services sociaux du Saguenay–Lac-Saint-Jean; and Montreal Neurological Institute (B.B.), McGill University, Québec, Canada.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
? Canadian Institute for Health Research (CIHR): New emerging team on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: from models to treatment strategies, 2 500 000 $/ 5 years (Brais Lab ? Y1: 168 239 $, Y2: 150 686 $, Y3: 163 063 $, Y4: 165 876 $, Y5: 161 630 $); 01-02-2012 to 31-01-2017. -Fondation de l?ataxie de Charlevoix-Saguenay CDN$ 200 00 20016 to 2018. -ERare, PREPARE consortium. CDN$75 000/year 2016-2020
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Gagnon [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Cynthia Gagnon: study concept and design, study supervision, analysis and interpretation of data. Isabelle Lessard: acquisition, analysis and interpretation of data, writing of the manuscript. Caroline Lavoie: acquisition of data, review of the manuscript. Isabelle Côté: analysis of data, statistical analysis, writing of the manuscript. Raphaël St-Gelais: interpretation of data, writing of the manuscript. Jean Mathieu and Bernard Brais: study concept and design, critical revision of manuscript for intellectual content.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS), The AAPS Journal, 26, 3, (2024).https://doi.org/10.1208/s12248-024-00925-7
    Crossref
  2. A juvenile-onset case of autosomal recessive spastic ataxia of charlevoix–saguenay with a novel mutation in the SACS gene, Annals of Movement Disorders, 6, 1, (36-38), (2023).https://doi.org/10.4103/aomd.aomd_15_22
    Crossref
  3. Digital health metrics reveal upper limb impairment profiles in ARSACS, Journal of the Neurological Sciences, 448, (120621), (2023).https://doi.org/10.1016/j.jns.2023.120621
    Crossref
  4. Toward a Better Understanding of Walking Speed in Ataxia of Charlevoix-Saguenay: a Factor Exploratory Study, The Cerebellum, 23, 4, (1377-1385), (2023).https://doi.org/10.1007/s12311-023-01646-x
    Crossref
  5. The Development of a New Patient-Reported Outcome Measure in Recessive Ataxias: The Person-Reported Ataxia Impact Scale, The Cerebellum, 23, 2, (512-522), (2023).https://doi.org/10.1007/s12311-023-01565-x
    Crossref
  6. Natural History of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: a 4-Year Longitudinal Study, The Cerebellum, 23, 2, (489-501), (2023).https://doi.org/10.1007/s12311-023-01558-w
    Crossref
  7. Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients, Annals of Neurology, 94, 3, (470-485), (2023).https://doi.org/10.1002/ana.26712
    Crossref
  8. Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix–Saguenay to develop patient-reported outcome, Orphanet Journal of Rare Diseases, 17, 1, (2022).https://doi.org/10.1186/s13023-022-02497-1
    Crossref
  9. Participation and Functional Independence in Adults With Recessive Spastic Ataxia of Charlevoix-Saguenay, Canadian Journal of Occupational Therapy, 89, 3, (315-325), (2022).https://doi.org/10.1177/00084174221088417
    Crossref
  10. First report of spastic ataxia of Charlevoix-Saguenay cases in Mexico. Novel SACS gene mutations identified, Neurology Perspectives, 2, 4, (214-223), (2022).https://doi.org/10.1016/j.neurop.2022.07.002
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share